Argitalpenak (34) XANDRA GARCÍA GONZÁLEZ argitalpenak

2023

  1. Hacia la excelencia en la atención farmacéutica al paciente quirúrgico

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 47, Núm. 1, pp. 26-30

  2. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

    Frontiers in Oncology, Vol. 13

  3. Pharmacogenetics in the Treatment of Huntington’s Disease: Review and Future Perspectives

    Journal of Personalized Medicine, Vol. 13, Núm. 3

  4. Presence of metallic components in transdermal drug delivery systems and risk of skin burns

    Farmacia Hospitalaria

2022

  1. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

    Clinical and Translational Oncology, Vol. 24, Núm. 3, pp. 483-494

  2. PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort

    Biomedicine and Pharmacotherapy, Vol. 146

  3. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy

    Clinical Microbiology and Infection, Vol. 28, Núm. 9, pp. 1287.e9-1287.e15

2021

  1. Clinical evaluation of pulmonary hypertension using patient-reported outcomes: a cross-sectional study

    BMC Pulmonary Medicine, Vol. 21, Núm. 1

  2. Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach

    Journal of Personalized Medicine, Vol. 11, Núm. 8

  3. Levels of tacrolimus after treatment for chronic hepatitis C with direct antiviral agents in solid organ transplant recipients

    International Journal of Clinical Pharmacy, Vol. 43, Núm. 3, pp. 731-736

  4. Pharmacogenetics to avoid adverse reactions in cardiology: Ready for implementation?

    Journal of Personalized Medicine, Vol. 11, Núm. 11

  5. Valganciclovir—Ganciclovir use and systematic therapeutic drug monitoring. An invitation to antiviral stewardship

    Antibiotics, Vol. 10, Núm. 1, pp. 1-18

2020

  1. Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis

    Pharmacological Research, Vol. 152

  2. Genetic Predictors of Long-term Response to Antitumor Necrosis Factor Agents in Pediatric Inflammatory Bowel Disease

    Journal of pediatric gastroenterology and nutrition, Vol. 71, Núm. 4, pp. 508-515

  3. Improving surgical antibiotic prophylaxis adherence and reducing hospital readmissions: A bundle of interventions including health information technologies

    European Journal of Hospital Pharmacy, Vol. 27, Núm. 4, pp. 237-242

  4. New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine

    Cancer Chemotherapy and Pharmacology, Vol. 86, Núm. 1, pp. 45-54

  5. Topical Administration of Amphotericin B as an Effective Adjuvant Treatment for a Deep Fungal Infection of Diabetic Foot Injury

    American journal of therapeutics, Vol. 27, Núm. 6, pp. e670-e671

2019

  1. Comments on: “Clinical utility of ABCB1 genotyping for preventing toxicity in treatment with irinotecan”

    Pharmacological Research

  2. Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution

    International Journal of Antimicrobial Agents, Vol. 53, Núm. 1, pp. 40-48

  3. Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin

    Journal of Oncology Pharmacy Practice, Vol. 25, Núm. 3, pp. 694-698